Listed

Parabilis Medicines, Inc.

PBLSNasdaqCIK 1657677HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$148.0k, Q2 FY2026
Operating income−$50.9m, Q2 FY2026
Net income−$52.5m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30period not labelled2026-03-31Q2 FY20262026-06-30
Revenue$mnot reported0.0Revenue, period not labelled, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported0.1Revenue, Q2 FY2026, three months to 2026-06-30$148.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Research and development$mnot reported30.1Research and development, period not labelled, three months to 2025-06-30$30.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported39.4Research and development, Q2 FY2026, three months to 2026-06-30$39.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Operating income$mnot reported(36.5)Operating income, period not labelled, three months to 2025-06-30−$36.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported(50.9)Operating income, Q2 FY2026, three months to 2026-06-30−$50.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Interest expense$mnot reported0.4Interest expense, period not labelled, three months to 2025-06-30$396.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported0.2Interest expense, Q2 FY2026, three months to 2026-06-30$210.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Net income$m(38.3)Net income, period not labelled, three months to 2025-03-31−$38.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(34.8)Net income, period not labelled, three months to 2025-06-30−$34.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(45.3)Net income, period not labelled, three months to 2026-03-31−$45.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(52.5)Net income, Q2 FY2026, three months to 2026-06-30−$52.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Diluted EPS$ per sharenot reported(22.28)Diluted EPS, period not labelled, three months to 2025-06-30−$22.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported(2.32)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Basic EPS$ per sharenot reported(22.28)Basic EPS, period not labelled, three months to 2025-06-30−$22.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported(2.32)Basic EPS, Q2 FY2026, three months to 2026-06-30−$2.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure

Balance sheet

Cash and equivalents$1.09bn, Q2 FY2026
Long-term debt$700.0k, Q2 FY2026
Shareholders' equity$1.05bn, Q2 FY2026
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31period not labelled2026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reportednot reported80.4Cash and equivalents, period not labelled, at 2025-06-30$80.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure27.7Cash and equivalents, period not labelled, at 2025-12-31$27.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported1,087Cash and equivalents, Q2 FY2026, at 2026-06-30$1.09bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Current assets$mnot reportednot reportednot reported29.4Current assets, period not labelled, at 2025-12-31$29.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported1,125Current assets, Q2 FY2026, at 2026-06-30$1.13bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Total assets$mnot reportednot reportednot reported80.8Total assets, period not labelled, at 2025-12-31$80.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported1,175Total assets, Q2 FY2026, at 2026-06-30$1.18bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Current liabilities$mnot reportednot reportednot reported56.8Current liabilities, period not labelled, at 2025-12-31$56.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported62.8Current liabilities, Q2 FY2026, at 2026-06-30$62.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Total liabilities$mnot reportednot reportednot reported97.3Total liabilities, period not labelled, at 2025-12-31$97.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported128Total liabilities, Q2 FY2026, at 2026-06-30$127.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Long-term debt$mnot reportednot reportednot reported0.6Long-term debt, period not labelled, at 2025-12-31$600.0k. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported0.7Long-term debt, Q2 FY2026, at 2026-06-30$700.0k. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Current portion of debt$mnot reportednot reportednot reported13.1Current portion of debt, period not labelled, at 2025-12-31$13.1m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported5.7Current portion of debt, Q2 FY2026, at 2026-06-30$5.7m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Short-term borrowings$mnot reportednot reportednot reported12.5Short-term borrowings, period not labelled, at 2025-12-31$12.5m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figurenot reported5.0Short-term borrowings, Q2 FY2026, at 2026-06-30$5.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure
Shareholders' equity$m(384)Shareholders' equity, period not labelled, at 2024-12-31−$383.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(421)Shareholders' equity, period not labelled, at 2025-03-31−$421.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(455)Shareholders' equity, period not labelled, at 2025-06-30−$455.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(526)Shareholders' equity, period not labelled, at 2025-12-31−$526.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure(570)Shareholders' equity, period not labelled, at 2026-03-31−$570.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure1,048Shareholders' equity, Q2 FY2026, at 2026-06-30$1.05bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure

Shares

Diluted shares (weighted)28.91m, Q2 FY2026
Line itemUnitperiod not labelled2025-06-30Q2 FY20262026-06-30
Diluted shares (weighted)m shares2.0Diluted shares (weighted), period not labelled, three months to 2025-06-302,019,111 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure28.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3028,908,277 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349168.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.